| At a glance | Persistent inattention and/or hyperactivity-impulsivity present before age 12 with cross-setting impairment. | Mood disorders with hypomanic (not manic) episodes; bipolar II has full depressive episodes, cyclothymia has chronic subthreshold oscillation. |
|---|
| Classic presentation | Inattention: careless mistakes, difficulty sustaining attention, doesn't listen, fails to follow through, organization difficulties, avoids sustained mental effort, loses things, easily distracted, forgetful; Hyperactivity-impulsivity: fidgets, leaves seat, runs/climbs inappropriately, can't engage quietly, 'on the go', talks… | Patient presents with depression and reports past 'best week of my life' periods of needing only 3 hours of sleep, completing massive projects, and spending impulsively — without ever being hospitalized or psychotic.; Hypomania: elevated/expansive or irritable mood, decreased need for sleep, increased energy and goal-directed activity,… |
|---|
| Workup / key labs | DSM-5-TR: (A) >=6 inattention and/or >=6 hyperactivity-impulsivity symptoms for >=6 months in children, or >=5 for individuals age 17 and older; (B) Several symptoms present before age 12; (C) Present in >=2 settings; (D) Clear interference with functioning; (E) Not better explained by another disorder. Specify combined, predominantly… | Bipolar II: ≥1 hypomanic episode (≥4 days, ≥3 of 7 symptoms, observable change, no marked impairment/psychosis/hospitalization) + ≥1 MDE; never met manic criteria. Cyclothymia: ≥2 yr (≥1 yr youth) of subthreshold hypomanic AND depressive symptoms, ≥half the time, no symptom-free interval >2 mo, criteria for an MDE, manic, or hypomanic… |
|---|
| Imaging | Not routinely indicated | Not routinely indicated; Neuroimaging if first episode late-life or focal neurologic findings |
|---|
| First-line treatment | Behavioral parent training and classroom interventions — first-line in preschool age (4-5 years) and adjunct at all ages; Stimulant — methylphenidate, lisdexamfetamine, mixed amphetamine salts (first-line pharmacotherapy school-age and older); titrate to effect over weeks; methylphenidate blocks dopamine and norepinephrine reuptake… | Bipolar II acute depression: quetiapine (best evidence; the only CANMAT first-line agent); lumateperone is also FDA-approved for bipolar II depression (CANMAT second-line), while lurasidone and cariprazine are approved only for bipolar I depression; Bipolar II maintenance: lithium (anti-suicide benefit), lamotrigine (especially if… |
|---|